Seeking Alpha

Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE ® (acalabrutinib) in ...
Business Wire

CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with ...
Nasdaq

AstraZeneca: Calquence Combo Enhances PFS In First-Line CLL In Phase III Trial

(RTTNews) - AstraZeneca (AZN.L, AZN) announced positive high-level results from an interim analysis of the AMPLIFY Phase III trial, showing that a fixed duration of the company's Calquence ...